Younger patients and low c-peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium-glucose cotransporter 2 inhibitor administration
© 2023 John Wiley & Sons Ltd..
AIM: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are available for individuals with type 1 diabetes, but appropriate use is recommended to prevent ketosis or ketoacidosis. This study aimed to evaluate the risk of ketosis in people with type 1 diabetes, focusing on the relationship between nutritional assessment, glycaemic status, c-peptide immunoreactivity (CPR) index and body composition.
MATERIALS AND METHODS: In total, 46 Japanese patients with type 1 diabetes were included, and dietary assessment from food photographs and ketone levels were evaluated before and after taking SGLT2is. The effect of diet on morning ketone levels was also investigated.
RESULTS: All patients had an increase in mean ketone concentrations after taking SGLT2is (before 0.12 ± 0.06 mmol/L, after 0.23 ± 0.16 mmol/L). A significant negative correlation was found between average morning ketone levels and age (r = -0.514, p < .001) and the CPR index (r = -0.523, p = .038) after taking SGLT2is. Using a mixed-effects model based on the results before starting the inhibitors, it was noted that both patient-to-patient and age, or patient-to-patient and capacity of insulin secretion, influenced the ketone levels. Multiple regression analysis showed that factors associated with the risk of increasing ketone levels after taking SGLT2is were younger age (β = -0.504, p = .003) and a low ratio of basal to bolus insulin (β = -0.420, p = .005).
CONCLUSIONS: When administering SGLT2is to patients with a low CPR index or younger patients with type 1 diabetes, adequate instructions to prevent ketosis should be given.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 25(2023), 12 vom: 12. Dez., Seite 3682-3689 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakajima, Hanako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C-Peptide |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.15262 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361653557 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361653557 | ||
| 003 | DE-627 | ||
| 005 | 20231226085609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.15262 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361653557 | ||
| 035 | |a (NLM)37667649 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakajima, Hanako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Younger patients and low c-peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium-glucose cotransporter 2 inhibitor administration |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are available for individuals with type 1 diabetes, but appropriate use is recommended to prevent ketosis or ketoacidosis. This study aimed to evaluate the risk of ketosis in people with type 1 diabetes, focusing on the relationship between nutritional assessment, glycaemic status, c-peptide immunoreactivity (CPR) index and body composition | ||
| 520 | |a MATERIALS AND METHODS: In total, 46 Japanese patients with type 1 diabetes were included, and dietary assessment from food photographs and ketone levels were evaluated before and after taking SGLT2is. The effect of diet on morning ketone levels was also investigated | ||
| 520 | |a RESULTS: All patients had an increase in mean ketone concentrations after taking SGLT2is (before 0.12 ± 0.06 mmol/L, after 0.23 ± 0.16 mmol/L). A significant negative correlation was found between average morning ketone levels and age (r = -0.514, p < .001) and the CPR index (r = -0.523, p = .038) after taking SGLT2is. Using a mixed-effects model based on the results before starting the inhibitors, it was noted that both patient-to-patient and age, or patient-to-patient and capacity of insulin secretion, influenced the ketone levels. Multiple regression analysis showed that factors associated with the risk of increasing ketone levels after taking SGLT2is were younger age (β = -0.504, p = .003) and a low ratio of basal to bolus insulin (β = -0.420, p = .005) | ||
| 520 | |a CONCLUSIONS: When administering SGLT2is to patients with a low CPR index or younger patients with type 1 diabetes, adequate instructions to prevent ketosis should be given | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 650 | 4 | |a carbohydrate | |
| 650 | 4 | |a ketone body | |
| 650 | 4 | |a nutritional therapy | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a C-Peptide |2 NLM | |
| 650 | 7 | |a Ketones |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Okada, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimura, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Goji |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsuhashi, Kazuteru |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Takuro |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Senmaru, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ushigome, Emi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hamaguchi, Masahide |e verfasserin |4 aut | |
| 700 | 1 | |a Fukui, Michiaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 25(2023), 12 vom: 12. Dez., Seite 3682-3689 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:12 |g day:12 |g month:12 |g pages:3682-3689 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.15262 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 12 |b 12 |c 12 |h 3682-3689 | ||